Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ASV AGEN2017+ QS-21 Stimulon adjuvant · 1 trial · 1 indication
Assessed by monitoring the frequency, duration, and severity of drug-related AEs by completing physical examinations and clinical evaluations; evaluating changes in vital signs; and laboratory blood and urine sample evaluations.
| Arm | Type | Description |
|---|---|---|
| ASV® AGEN2017 | EXPERIMENTAL | ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine |
| Name | Type | Description |
|---|---|---|
| ASV® AGEN2017 + QS-21 Stimulon® adjuvant | BIOLOGICAL | Neoantigen Vaccine |
Inclusion Criteria: 1. Signed, written informed consent. 2. Age ≥18 years. 3. Diagnosis of solid cancer that has been completely resected, NED, and eligible for observation only as SOC yet remain at risk of relapse per Investigator discretion. These include subjects diagnosed with malignant melanom...
ASV AGEN2017+ QS-21 Stimulon adjuvant is an investigational monoclonal antibody being developed for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with one completed trial evaluating its immunogenicity in patients with adult solid tumors.
ASV AGEN2017+ QS-21 Stimulon adjuvant is being developed by Agenus Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AGEN. The company is conducting clinical research on this investigational therapy for oncology applications.
ASV AGEN2017+ QS-21 Stimulon adjuvant is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and immunogenicity in patients with solid tumors.
ASV AGEN2017+ QS-21 Stimulon adjuvant has one completed clinical trial registered under NCT03673020, titled "Phase 1a Study to Evaluate Immunogenicity of ASV®". This Phase 1 study enrolled 3 adult patients with solid tumors in the United States and was not randomized or blinded.
Yes, ASV AGEN2017+ QS-21 Stimulon adjuvant is also known as ASV. The clinical trial NCT03673020 refers to the drug as ASV® in its title, indicating that ASV is an alternative name for this investigational monoclonal antibody being developed by Agenus Inc.